Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development.

Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development.

Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development.

NIBR-LTSi is a selective small-molecule inhibitor of LATS kinase . It agonizes YAP signaling and promotes tissue regeneration in vitro and in vivo, supporting future research on the regenerative potential of the YAP/Hippo pathway.

NIBR-LTSi is a selective small-molecule inhibitor of LATS kinase . It agonizes YAP signaling and promotes tissue regeneration in vitro and in vivo, supporting future research on the regenerative potential of the YAP/Hippo pathway.

NIBR-LTSi is a selective small-molecule inhibitor of LATS kinase . It agonizes YAP signaling and promotes tissue regeneration in vitro and in vivo, supporting future research on the regenerative potential of the YAP/Hippo pathway.

DCZ0415 is a potent inhibitor of TRIP13. DCZ0415 impairs nonhomologous end joining repair and inhibits NF-κB activity. It triggers anti-myeloma effects both in vitro, and in vivo, and primary cells obtained from myeloma patients resistant to drugs.

NIBR-LTSi is a selective small-molecule inhibitor of LATS kinase . It agonizes YAP signaling and promotes tissue regeneration in vitro and in vivo, supporting future research on the regenerative potential of the YAP/Hippo pathway.

DCZ0415 is a potent inhibitor of TRIP13. DCZ0415 impairs nonhomologous end joining repair and inhibits NF-κB activity. It triggers anti-myeloma effects both in vitro, and in vivo, and primary cells obtained from myeloma patients resistant to drugs.

Iclepertin(BI-425809) is a potent and selective inhibitor of glycine transporter 1 (GlyT1) that increases glycine levels in the cerebrospinal fluid (CSF).